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The association between diabetes mellitus (DM) and high mortality linked to cardiovascular disease (CVD) is a major concern
worldwide. Clinical and preclinical studies have demonstrated a variety of diastolic and systolic dysfunctions in patients with
type 2 diabetes mellitus (T2DM) with the severity of abnormalities depending on the patients’ age and duration of diabetes. The
cellular basis of hemodynamic dysfunction in a type 2 diabetic heart is still not well understood. The aim of this review is to
evaluate our current understanding of contractile dysfunction and disturbances of Ca2+ transport in the Goto-Kakizaki (GK)
diabetic rat heart. The GK rat is a widely used nonobese, nonhypertensive genetic model of T2DM which is characterized by
insulin resistance, elevated blood glucose, alterations in blood lipid proﬁle, and cardiac dysfunction.

1. Use of the Goto-Kakizaki Diabetic Rat
Diabetes mellitus (DM) is a metabolic disease characterized
by abnormal glucose homeostasis and defects in insulin
metabolism. Cardiovascular disease (CVD) is the leading
cause of death in the diabetic population. However, the
molecular mechanisms underlying diabetic cardiomyopathy
remain unclear.
Animal models are increasingly being used to elucidate
the mechanisms underlying diabetic cardiomyopathy in both
type 1 and type 2 diabetes. One of the most widely used
animal models of type 2 diabetes mellitus (T2DM) is the
Goto-Kakizaki (GK) rat. The GK rat is a polygenic nonobese
model of T2DM. This model is generated by selective
inbreeding of mildly glucose-intolerant Wistar rats over
many generations [1]. At least 17 genes associated with
metabolism, signal transduction, receptors, and secreted
factors are involved in the pathogenesis of diabetes in the
GK rat [2]. The general characteristics of the GK rat

include fasting hyperglycemia, impaired insulin secretion in
response to glucose both in vivo and in isolated pancreata,
raised glycosylated hemoglobin, hepatic and peripheral
insulin resistance, altered heart and body weight, and a
variety of late complications, including cardiomyopathy,
nephropathy, and neuropathy [1, 3–11]. In contrast to many
other non-insulin-dependent rodent models, GK rats are
non-obese [1, 12].
Three genetic loci are responsible for coding and transferring diabetic pathology to the fetus, and these include
genes that are responsible for a reduction in β-cell mass
and reduced insulin secretion [12]. During the prediabetic
period (ﬁrst three weeks after birth), animals have reduced
body weight and do not show hyperglycemia. After weaning,
many changes occur which include hyperglycemia, impaired
glucose-induced insulin secretion (due to defective prenatal
β-cell proliferation and reduction in β-cell mass), reduced
insulin sensitivity in the liver, and moderate insulin resistance in peripheral tissues [12, 13].
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Persistent hyperglycemia over time provokes pancreatic
islet inﬂammation, oxidative stress, ﬁbrosis, and ﬁnally β-cell
dysfunction. In fact, the pancreatic islets of adult GK rats
show decreased β-cell number and insulin content as compared to their age-matched control animals [12].
GK rats have been considered as one of the best nonobese
type 2 diabetic animal models. GK rats exhibit valuable characteristics that are more or less common and functionally
present in human diabetic patients. This animal model is
considered appropriate to examine various pathologic mechanisms of T2DM [12, 14]. As mentioned earlier, reduced
β-cell mass and reduced β-cell function are key characteristics found in this animal model [15]. Therefore, it is clear that
GK rats form an important resource in preclinical T2DM
research [16] in order to study the role of β-cell compensation in the pathogenesis of T2DM.
An earlier study has shown that GK islet ﬁbrosis is
accompanied by marked inﬂammation which is a characteristic that has been reported in islets of type 2 diabetic
patients [17]. Other changes that are common between GK
rats and human diabetic patients include decreased activity
of glucose transporter (GLUT-2), glycerol-3-phosphate
dehydrogenase (GPDH), and glucokinase and changes in
the lipid proﬁle [12].
As in humans, GK rats also develop renal lesions, structural changes in peripheral nerves, and retinal damage [13].
For example, in adult GK rats, signiﬁcant morphological
alterations in kidneys occur in response to chronic hyperglycemia which are similar to that in human diabetic patients
[18, 19]. These morphological changes in kidneys include
glomerulosclerosis, proliferation of mesangial cells, atrophy
of basement membrane, and tubulointerstitial ﬁbrosis [20].

2. Other Animal Models of Type 2 Diabetes
T2DM is characterized by insulin resistance and the inability
of the β-cell to suﬃciently compensate, which leads to
hyperglycemia [21]. In addition, T2DM is closely associated
with obesity which is one of the main pathological causes
of insulin resistance [15, 22]. Many animal models are
therefore obese as a result of naturally occurring mutations
or genetic manipulation and are useful in understanding
obesity-induced insulin resistance and its eﬀects. These are
divided into monogenic models, polygenic models, and
diet-induced models [23]. The general characteristics for
these obese models are insulin resistance and impaired
glucose tolerance. In other words, these models lack
suﬃcient insulin secretion required to compensate for the
insulin resistance as part of the obesity (obesity-induced
hyperglycemia) [13, 23].
Lepob/ob mice, Leprdb/db mice, and Zucker diabetic fatty
rats are the most commonly used models of monogenic
obesity. They have a disrupted leptin signaling pathway,
leading to hyperphagia and obesity [13]. Polygenetic animal
models, however, provide more accurate models of the
human condition [15]. These include KK-AY mice, New
Zealand obese (NZO) mice, TallHo/Jng mice, and Otsuka
Long Evans Tokushima Fat (OLETF) rat. Obesity can also
be induced by feeding the rodent a high-fat diet (diet-
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induced models). The weight gain in these animals is
associated with insulin resistance and abnormal glucose
metabolism [12, 13, 23].
In contrast to the animal models mentioned above, the
GK rat is a non-obese animal model of T2DM. It is characterized by reduced β-cell mass and/or β-cell function [24]. The
GK rat is glucose intolerant and displays defective glucoseinduced insulin secretion. Furthermore, the development of
insulin resistance does not seem to be the main initiator of
hyperglycemia. Instead, the defective glucose metabolism is
regarded to be due to reduced β-cell mass [25] and/or
function [26]. Adult GK rats show a 60% decrease in their
total pancreatic β-cell mass. Blood glucose is elevated only
after the ﬁrst 3-4 weeks of animal’s age, and blood glucose
rises signiﬁcantly after a glucose challenge [13, 27]. The GK
model is characterized by early hyperglycemia, hyperinsulinemia, and insulin resistance, [1, 12]. Other examples of
non-obese animal models of T2DM are the C57BL/6
(Akita) mutant mouse, the Cohen diabetic rats, and the
spontaneously diabetic Torri (SDT) rats [13].

3. Blood Chemistry in the Goto-Kakizaki
Diabetic Rat
Blood insulin, glucose, and lipid proﬁles in the GK rats
compared to controls are summarized in Tables 1, 2, and 3,
respectively. Blood insulin is either unaltered [28–34] or
increased [29, 34, 35] in the GK rats (Table 1). Fasting blood
glucose and nonfasting blood glucose are slightly increased
[10, 11, 28–48] and urine glucose is increased [30] in the
GK rat. Following a glucose challenge, in the fasted state,
blood glucose is signiﬁcantly elevated at 30, 60, and
120 min [29, 37–40, 44, 46, 48–50] in the GK rat indicating
end organ resistance to the action of insulin (Table 2). Blood
cholesterol is increased [29, 35, 43, 44] whilst high-density
lipoprotein cholesterol may be either unaltered [31] or
increased [44] and low-density lipoprotein cholesterol is
unaltered [31, 44] in the GK rat compared to controls. Blood
free fatty acids are either unaltered [11, 31] or increased
[38, 45] in the GK rats compared to controls. Triglycerides
are either increased [38, 43–45] or unaltered [2, 30, 45] in
the GK rats compared to controls (Table 3). Part of the variability in blood chemistry may be attributed to the age of
the animals and dietary regime. In summary, the GK rat
displays hyperglycemia, insulin resistance, and disturbances
in lipid proﬁle.

4. Body and Heart Weight in the Goto-Kakizaki
Diabetic Rat
Body weight and heart weight measures in GK rats compared
to controls are summarized in Tables 4 and 5, respectively.
Body weight is either unaltered [31, 34, 36, 39–41, 46, 50],
decreased [2, 10, 11, 28–30, 32, 35, 38, 42–46], or increased
[34, 47, 48] in the GK rat (Table 4). Heart weight is generally
increased [29, 40, 41, 48, 49] but may also be decreased
[10, 43] or unaltered [11, 39]; left ventricular weight is
either decreased [43, 45] or increased [32]; left ventricular
thickness is increased [40] or unaltered [36]; right
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Table 1: Blood insulin in the GK rat.

Parameter

INS

Age

Control versus GK

Reference

5, 15, and 22 w
7, 11, and 15 w
14–16 w
16 w
16 w
18 w
20 w
20 w
5, 15, and 22 w
24 w
18 and 30 w

79.2 versus 77.4 [5], 151.4 versus 165.2∗ [15], and 171.5 versus 234.1∗ [22] (pmol/l)
Increased at 7∗ and 11 w∗ , unaltered at 15 w
150 versus 176 pmol/l NSD
1.60 versus 2.11∗ (μg/ml)
6.3 versus 5.3 mU/l NSD
4.9 versus 2.1 ng/ml NSD
4.1 versus 2.6 ng/ml NSD
1.7 versus 2.2 pg/ml NSD
79.2 versus 77.4 [5], 151.4 versus 165.2 [15], and 171.5 versus 234.1∗ [22] (pmol/l)
14.5 versus 12.32 μg/ml NSD
132 versus 87∗ [18] and 240 versus 85∗ [30] (pmol/ml)

[34]
[29]
[28]
[35]
[30]
[31]
[32]
[33]
[34]
[2]
[45]

INS: insulin; NSD: no signiﬁcant diﬀerence. ∗ Signiﬁcant diﬀerence.

ventricular weight is either unaltered [45] or decreased
[45] in GK rats compared to controls. Heart-weight-tobody-weight ratio is increased [10, 11, 29, 30, 32, 33, 36, 40,
50] but may also be unaltered [31, 41, 48]; heart-weightto-femur-length ratio is increased [44]; left-ventricle-tobody-weight ratio is increased [36, 43, 45, 51]; right-ventricle-to-body-weight ratio is unaltered [45]; biventricularweight-to-body-weight and biventricular-weight-to-tibiallength ratios are increased [28, 45] (Table 5). In summary,
the various heart to body ratio measures and the structural
changes observed in the heart of this nonobese, nonhypertensive animal model provide evidence for regional cardiac
hypertrophy.
Earlier studies have reported that chronic mild hyperglycemia produces molecular and structural correlates of
hypertrophic myopathy in GK rats [40]. Several mechanisms whereby hyperglycemia may induce left ventricle
remodeling have been proposed. One of these mechanisms
is the increased activity of proﬁbrotic and prohypertrophic
cytokine transforming growth factor-β1 (TGF-β1) in the
ventricular tissue [52]. TGF-β1 reproduces most of the
hallmarks seen in structural remodeling. Speciﬁcally,
TGF-β1 induces expression levels of extracellular matrix
(ECM) constituents by cardiac ﬁbroblasts (i.e., ﬁbrillar collagen, ﬁbronectin, and proteoglycans), self-ampliﬁes its
own expression in both cardiac myocytes and ﬁbroblast
[53, 54], and stimulates the proliferation of ﬁbroblasts
and their phenotypic conversion to myoﬁbroblasts [55,
56]. D’Souza et al. have shown that the increased activity
of TGF-β1 and phosphorylation of protein kinase B
(PKB)/Akt and its downstream eﬀectors mediate the
hypertrophic eﬀects of TGF-β1 in the prediabetic GK left
ventricle [36]. The hypertrophic events were also sustained
in the aging GK myocardium [40]. Earlier studies have
suggested that enhanced activity of myocardial Na+/H+
exchanger plays a role in the molecular mechanisms
involved in cardiac hypertrophy. It is likely that the activation of the Akt pathway mediates the hypertrophic eﬀect
of myocardial Na+/H+ exchanger in the GK rat model of
T2DM [28]. Interestingly, several studies have shown that

female rat hearts are more hypertrophied than male hearts
[10, 32, 57].

5. In Vivo Hemodynamic Function in the
Goto-Kakizaki Rat Heart
In vivo hemodynamic function and related measures in GK
rats compared to controls are summarized in Table 6. Heart
rate is either unaltered [28, 30–33, 37, 45, 58] or reduced [2,
34, 46] in the GK rat. Systolic blood pressure is unaltered
[28, 30, 31, 33, 58] or increased [32, 34, 37, 58]; whilst
diastolic blood pressure is increased [30, 34], mean
arterial pressure is unaltered [35], increased [37], or
reduced [30] in GK rat. Rate for pressure development
(+dP/dt) and decline (–dP/dt) in left ventricle is
unaltered [30, 45] in the GK rat. Ejection fraction is
reduced [28, 51], increased [44], or unaltered [30, 33];
fractional shortening is reduced [32, 51] or unaltered [2, 33,
45]; cardiac output is unaltered [33] or decreased [51] in
the GK rat. Coronary blood ﬂow is increased [29] or
reduced [2] in GK rats compared to controls. In summary,
the GK rat heart may display a variety of abnormal
hemodynamic characteristics including alterations in heart
rate, blood pressure, blood pumping capability, and altered
coronary blood ﬂow.

6. Hemodynamic Function in the
Isolated Perfused Goto-Kakizaki Rat Heart
Heart rate in the isolated perfused heart is lower in
comparison to the heart rate in vivo in GK and control
hearts (Table 7). Isolated perfused heart rate is unaltered
[10, 11, 31, 50] in GK rats. Left ventricle +dP/dt and –dP/dt
are either unaltered [10, 31, 59] or reduced [51] in the GK
rat. Coronary ﬂow is either reduced [11, 31] or unaltered
[10] in GK rats compared to controls. Collectively, the GK
rat heart displays a variety of abnormal hemodynamic
characteristics, including altered rate of development and
relaxation of ventricular contraction and altered coronary
ﬂow compared to controls.
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Table 2: Glucose proﬁle in the GK rat.

Parameter

FBG

NFBG

UG

Age

Control versus GK

Reference

8w
5, 15, and 22 w
7, 11, and 15 w
16 w

76.2 versus 107.0∗ (mg/dl)
∗
6.14 versus 7.49 [5], 7.56 versus 8.71∗ [15], and 5.26 versus 9.02∗ [22] (mmol/l)
Increased at 7∗ , 11∗ , and 15∗ (w)
4.8 versus 8.8∗ (mmol/l)
Increased∗

[36]
[34]
[29]
[35]

26 w

∗

[37]

26 w
17 m
18 m
18 m

65.8 versus 99.1 (mg/dl)
72.1 versus 151.5∗ (mg/dl)
95.2 versus 131.4∗ (mg/dl)
44 versus 51 mg/dl NSD

[38]
[39]
[40]
[50]

8–10 w
11 w
12 w
14–16 w
16 w
18 w
20 w
20 w
5, 15, and 22 w
26 w
18 and 30 w
3, 6, and 15 m
5–8 m
9–14 m
10 m
10-11 m
17 m

118.40 versus 166.40∗ (mg/dl)
7.40 versus 9.18∗ (mM)
9.02 versus 26.57∗ (mmol/l)
9.4 versus 14.3∗ (mmol/l)
8.5 versus 12.8∗ (mmol/l)
6.0 versus 12.7∗ (mM)
7.5 versus 17.9∗ (mmol/l)
4.9 versus 8.2∗ (mmol/l)
∗
6.14 versus 7.49 [5], 7.56 versus 8.71∗ [15], and 5.26 versus 9.02∗ [22] (mmol/l)
204.42 versus 531.71∗ (mg/dl)
18.7 versus 24.9∗ [18] and 19.2 versus 27.6∗ [30] (μmol/ml)
49.6 versus 48.4 [3], 48.1 versus 73.3∗ [6], and 68.6 versus 113.3∗ [15] (mg/dl)
11.3 versus 14.7∗ (mmol/l)
10.3 versus 17.0∗ (mM)
95.77 versus 143.06∗ (mg/dl)
91.67 versus 161.29∗ (mg/dl)
101.4 versus 188.8∗ (mg/dl)

[41]
[42]
[43]
[28]
[30]
[31]
[32]
[33]
[34]
[44]
[45]
[46]
[10]
[11]
[47]
[48]
[39]

16 w

0.13 versus 0.73∗ (g/l)

[30]

∗

∗

∗

OGTT

8w
15 w
16 w
26 w
26 w
10-11 m
15 m
17 m
18 m
18 m

Elevated at 30 , 60 , and 120 (min)
Elevated at 30∗ , 60∗ , and 120∗ (min)
Elevated at 30∗ and 60∗ (min)
Elevated at 15∗ and 60∗ (min)
83.2 versus 303.4∗ (mg/dl) at 120 min
93.93 versus 236.27∗ (mg/dl) at 120 min
183.3 versus 276.9∗ (mg/dl) at 120 min
148.1 versus 570.8∗ (mg/dl) at 120 min
Elevated at 30∗ , 60∗ , 120∗ , and 180∗ (min)
153.4 versus 436.3∗ (mg/dl) at 180 min

[36]
[29]
[37]
[44]
[38]
[48]
[46]
[39]
[40]
[50]

OGTT

15 w

Increased∗ area under curve

[29]

HbA1c

25 w
5–8 m

3.5 versus 5.4∗ (%)
4.0 versus 4.8∗ (%)

[38]
[10]

7, 11, and 15 w

Increased at 7∗ , 11∗ , and NSD 15 (w)

[29]

HOMA-IR

FBG: fasting blood glucose; NFBG: nonfasting blood glucose; UG: urine glucose; OGTT: oral glucose tolerance test; HbA1c: glycated hemoglobin A1c;
HOMA-IR: homeostasis model assessment-estimated insulin resistance; NSD: no signiﬁcant diﬀerence. ∗ Signiﬁcant diﬀerence.

7. Contraction in Ventricular
Myocytes from the Goto-Kakizaki Rat Heart
Characteristics of shortening in myocytes from GK rats compared to controls are shown in Table 8. Myocyte diameter,

surface area, cross-sectional area, and cell capacitance were
increased [28, 30, 33, 36, 40, 51], and resting cell length
may be unaltered [10, 39, 41, 50] or increased [47] in
myocytes from the GK rat. In electrically stimulated myocytes, the time-to-peak (TPK) shortening was prolonged
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Table 3: Lipid proﬁle in the GK rat.

Parameter

Age

Control versus GK

Reference

7, 11, and 15 w
12 w
16 w
16 w
26 w

Increased at 7∗ , 11∗ , and 15∗ (weeks)
1.34 versus 2.15∗ (mmol/l)
1.71 versus 1.98∗ (mmol/l)
70 versus 93 mg/dl NSD
55.57 versus 93.0∗ (mg/dl)

[29]
[43]
[35]
[30]
[44]

HDL CHOL

18 w
26 w

26.9 versus 29.1 mg/ml NSD
22.0 versus 41.85∗ (mg/dl)

[31]
[44]

LDL CHOL

18 w
26 w

35.4 versus 39.5 mg/ml
20.42 versus 25.34 mg/dl

[31]
[44]

FFA

18 w
18 and 30 w
26 w
9–14 m

0.61 versus 0.54 mM NSD
0.30 versus 0.60∗ [18] and 0.41 versus 0.53∗ [30] (μmol/ml)
0.55 versus 1.3∗ (mM)
0.2 versus 0.3 mM NSD

[31]
[45]
[38]
[11]

TG

12 w
16 w
16 w
24 w
26 w
26 w
18 and 30 w

0.54 versus 1.21∗ (mmol/l)
1.72 versus 0.85∗ (mmol/l)
67 versus 60 mg/dl NSD
877.01 versus 1219.97 μmol/l NSD
98.2 versus 134.9∗ (mg/dl)
65.14 versus 129.42∗ (mg/dl)
0.74 versus 0.91 [18] and 0.93 versus 1.35∗ [30] (mg/ml)

[43]
[35]
[30]
[2]
[38]
[44]
[45]

CHOL

CHOL: cholesterol; HDL: high-density lipoproteins; LDL: low-density lipoproteins; FFA: free fatty acids; TG: Triglycerides; NSD: no signiﬁcant diﬀerence.
∗
Signiﬁcant diﬀerence.

[39, 41, 47] or unaltered [48, 50] and the time-tohalf (THALF) relaxation of shortening may be unaltered
[41, 47, 48] or shortened [50] or lengthened [39] in myocytes
from the GK rat. Amplitude of shortening may be unaltered
[10, 41, 48, 50] or increased [39] in myocytes from the GK
rat. In summary, ventricular myocytes from the GK rat heart
tend to be larger in size and have prolonged time course
and generally similar amplitude of contraction compared
to myocytes from the control heart.
During the process of excitation-contraction coupling
(ECC), the arrival of an action potential causes depolarization of the cardiac myocyte plasma membrane. This depolarization opens voltage-gated L-type Ca2+ channels in the
plasma membrane. The entry of small amounts of Ca2+
through these channels triggers a large release of Ca2+
from the sarcoplasmic reticulum (SR) via activation of the
ryanodine receptor (RyR), by the process termed calciuminduced calcium release (CICR). The transient rise in intracellular Ca2+ (Ca2+ transient) results in the binding of Ca2+
to troponin C which initiates and regulates the process of
cardiac muscle cell contraction. During the process of
relaxation, Ca2+ is pumped back into the SR via the SR
Ca2+-ATPase (SERCA2) and extruded from the cell,
primarily via the Na+/Ca2+ exchanger (NCX) [60, 61].
Changes in the kinetics of shortening observed in myocytes
of GK rats may be attributed, at least in part, to
alternations in ventricular myocardial stiﬀness. Earlier
studies have demonstrated increased collagen deposition
and increased ventricular stiﬀness in diﬀerent experimental
models of T2DM, which in turn were associated with

altered kinetics of myocardial contraction [62, 63]. The
observed disturbance in myocyte shortening may also be
attributed to the alternation in the proﬁle of expression of
mRNA encoding various proteins involved in excitationcontraction coupling [48].

8. Intracellular Ca2+ in Ventricular Myocytes
from the Goto-Kakizaki Rat Heart
Characteristics of intracellular Ca2+ in myocytes from GK
rats compared to controls are shown in Table 9. Resting
intracellular Ca2+ is unaltered [10, 41, 47, 48] or increased
[28]; TPK Ca2+ transient is unaltered [39, 41, 48, 50] or prolonged [47]; THALF decay of the Ca2+ transient is unaltered
[39, 47, 48, 50] or shortened [41]; and the amplitude of the
Ca2+ transient is unaltered [10, 41, 48], increased [47, 50],
or decreased [39] in myocytes from the GK rat. In wholecell patch clamp experiments, the amplitude, inactivation,
and restitution of L-type Ca2+ current are unaltered [48] in
myocytes from GK rats compared to controls.
Since intracellular Ca2+ in cardiac cells is maintained by
2+
Ca inﬂux (through L-type Ca2+ channels; the primary
trigger for SR Ca2+ release) and eﬄux (through NCX; the
major pathway for Ca2+ eﬄux from the cell) [64], as well as
Ca2+ release (via the ryanodine receptors) and uptake by
both SR (through SERCA2) and mitochondria, it is possible
that the observed diﬀerences in these results may be
attributed to diﬀerential changes in Ca2+ transport activities
in these organelles. Furthermore, the observed alterations in
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Table 4: Body weight of the GK rat.

Parameter

BW

Age

Control versus GK

Reference

5, 15, and 22 w
8w
8–10 w
11 w
12 w

[34]
[36]
[41]
[42]
[43]

15 w

82.0 versus 106.9∗ [5], 311.8 versus 315.0∗ [15], and 464.3 versus 417.8∗ [22] (g)
325.25 versus 329.00 g NSD
218.50 versus 246.40 g NSD
402 versus 275∗ (g)
432 versus 353∗ (g)
Reduced∗

14–16 w
16 w
16 w
18 w
20 w
5, 15, and 22 w
24 w
26 w
26 w
18 and 30 w
2, 7, and 10 m
5–8 m
9–14 m
10 m
10-11 m
17 m
18 m
18 m

376 versus 330∗ (g)
481.3 versus 414.0∗ (g)
450 versus 331∗ (g)
376 versus 372 g NSD
437 versus 385∗ (g)
∗
82 versus 106.9 [5], 311.8 versus 315 [15], and 464.3 versus 417.8 [22] (g)
491.67 versus 334.17∗ (g)
453.8 versus 401.7∗ (g)
402.3 versus 351.4∗ (g)
501 versus 386∗ [18] and 643 versus 427∗ [30] (g)
205.7 versus 230.3 [2], 469.9 versus 417.5∗ [7], and 494.0 versus 406.3∗ [10] (g)
559.5 versus 379.6∗ (g)
628 versus 396∗ (g)
383.31 versus 442.38∗ (g)
400.3 versus 443.64∗ (g)
436 versus 399 g NSD
418.7 versus 413.4 g NSD
513.4 versus 457.9 g NSD

[28]
[35]
[30]
[31]
[32]
[34]
[2]
[44]
[38]
[45]
[46]
[10]
[11]
[47]
[48]
[39]
[40]
[50]

[29]

BW: body weight; NSD: no signiﬁcant diﬀerence. ∗ Signiﬁcant diﬀerence.

intracellular Ca2+ may also be due to diﬀerences in the stage
and severity of diabetes [65, 66].
It is well known that alterations in SR Ca2+ uptake and
release mechanisms would impair cardiac cell function.
Several studies have reported changes in cardiac SR Ca2+
transport during the development of chronic diabetes
[67–71]. For example, Ganguly et al. reported that a decrease
in Ca2+ uptake activity by SR was associated with a decrease
in SERCA2a activity [68]. Furthermore, Golfman et al.
showed that SR ATP-dependent Ca2+ uptake activity was
markedly decreased in the diabetic rat heart [72]. Yu et al.
reported a reduction in both SR Ca2+ content and ryanodine
binding sites in diabetic hearts, indicating that the SR functions of storage and release of Ca2+ were depressed [73]. It
should be noted that prolonged depression of the SR Ca2+
uptake activity in chronic diabetes may contribute to the
occurrence of intracellular Ca2+ overload [65].
In our recently published data, L-type Ca2+ current and
2+
Ca transients were simultaneously measured in endocardial (ENDO) and epicardial (EPI) myocytes from the left
ventricle of GK rats [74]. Consistent with previous ﬁndings
[48], the amplitude of L-type Ca2+ current, over a wide range
of test potentials, was unaltered in ENDO and EPI myocytes
from the left ventricle of GK rat. However, the amplitude of
the Ca2+ transients was reduced and by similar extents, in

ENDO and EPI myocytes from the GK rat heart. The THALF
decay of the Ca2+ transients was reduced in EPI and ENDO
myocytes from GK rats compared to controls. Interestingly,
while a reduction in the amplitude of L-type Ca+ current
has been reported in earlier studies on a diabetic heart
[75, 76], it does not necessarily explain the reduced Ca2+
transients. This is because many reports show no change in
L-type Ca2+ current despite the reduction in both contractions and Ca2+ transients [48, 74, 77–79]. Instead, reduction
of Ca2+ transients and the consequent contractile dysfunction may be due to depletion of SR Ca2+, which may result
from RYR-dependent Ca2+ leak, an increased Ca2+ extrusion
through NCX, or a reduced function of SERCA [61, 80]. Further experiments will be required to investigate the role of SR
in Ca2+ transport in myocytes from the GK rat. Sheikh et al.
[81] demonstrated that cardiac endothelial cells from diabetic rats treated with NCX inhibitor have higher intracellular Ca2+ transient peaks as compared to controls. This
ﬁnding supports the idea that altered activity of sarcolemmal
NCX during Ca2+ eﬄux contributes to the decrease in
Ca2+ transient-observed GK myocytes. Previous experiments in ventricular myocytes from the streptozotocininduced diabetic rats have reported reduced caﬀeine-evoked
Ca2+ transients [82–91], SERCA2 activity, and Ca2+ uptake
[83, 88, 92–94] and decreased SR Ca2+ channel (ryanodine
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Table 5: Heart weight and other heart-related measurements in the GK rat.
Parameter

Age

Control versus GK

Reference

8w
8–10 w
12 w

[36]
[41]
[43]

15 w

0.807 versus 0.927∗ (g)
0.96 versus 1.05∗ (g)
1.14 versus 0.98∗ (g)
Increased∗

5–8 m
9–14 m
10-11 m
17 m
18 m

1700 versus 1460∗ (mg)
2.0 versus 1.8 g NSD
1.37 versus 1.60∗ (g)
1.52 versus 1.50 g NSD
1.22 versus 1.41∗ (g)

[10]
[11]
[48]
[39]
[40]

12 w
18 and 30 w

[43]
[45]

20 w

0.81 versus 0.68∗ (g)
1.12 versus 0.86∗ [18] and 1.32 versus 1.03∗ [30] (g)
Increased∗

LVT

8w
18 m

2.98 versus 3.15 mm NSD
3.08 versus 3.35∗ (mm)

[36]
[40]

RVW

18 and 30 w

0.30 versus 0.26 [18] and 0.32 versus 0.28∗ [30] (g)

[45]

HW

LVW

∗

0.248 versus 0.281 (g/100 g)
4.43 versus 4.33 mg/g NSD
Increased∗

8 weeks
8–10 w
15 w

HW/BW

HW/FL

[29]

[32]

[36]
[41]
[29]

∗

16 w

2.96 versus 3.73

[30]

18 w

[31]

20 w

2.2 versus 2.2 NSD
Increased∗

20 w

Increased∗

[33]

[32]

∗

9–14 m

3.1 versus 4.5

[11]

5–8 m
10-11 m
18 m
18 m

3.0 versus 3.8∗ (mg/g)
3.43 versus 3.61 mg/g NSD
0.21 versus 0.34∗ (g/100 g)
3.36 versus 4.10∗ (mg/g)

[10]
[48]
[40]
[50]

26 w

0.44 versus0.49∗

[44]

∗

LV/BW

8w
12 w
18 and 30 w
6m

1.76 versus 1.98 (mg/g)
1.85 versus 1.95∗ (mg/g)
2.16 versus 2.24∗ [18] and 2.06 versus 2.40∗ [30] (mg/kg)
0.20 versus 0.24∗ (%)

[36]
[43]
[45]
[51]

RV/BW

18 and 30 (w)

0.60 versus 0.71 [18] and 0.50 versus 0.66 [30] (mg/g)

[45]

14–16 w

Increased∗

[28]

BVW/BW
BVW/TL

∗

∗

18 and 30 w

2.76 versus 2.94 [18] and 2.56 versus 3.06 [30] (mg/g)

[45]

14–16 w

Increased∗

[28]

HW: heart weight; LVM: left ventricular weight; LVT: left ventricular thickness; RVW: right ventricular weight; BW: body weight; FL: femur length;
BVW: biventricular weight; TL: tibial length; NSD: no signiﬁcant diﬀerence. ∗ Signiﬁcant diﬀerence.

receptor) activity [87, 95] suggesting decreased SR Ca2+ content, Ca2+ uptake, and Ca2+ release mechanisms in ventricular myocytes from the streptozotocin-induced diabetic rat.
Under pathological conditions, such as chronic diabetes,
the mitochondria are able to accumulate large amounts of
Ca2+, which serves as a protective mechanism during cardiac dysfunction and intracellular Ca2+ overload. Therefore, altered mitochondrial uptake of Ca2+ during diabetes
may contribute to the reported decreased Ca2+ transients.
Although the mitochondria contribute to Ca2+ signaling,

their exact role in diabetic cardiomyopathy remains
to be investigated.
Recent investigations, using animal models, suggest that
mitochondrial dysfunction may also play a critical role in
the pathogenesis of diabetic cardiomyopathy [65, 71]. Potential mechanisms that contribute to mitochondrial impairment in diabetes include altered energy metabolism [96–99]
oxidative stress [100–102], altered mitochondrial dynamics
and biogenesis [103, 104], cell death [105, 106], and impaired
mitochondrial Ca2+ handling [107, 108].
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Table 6: In vivo hemodynamic function in the GK rat.

Parameter

Age

Control versus GK

Reference

15 and 22 w
14–16 w
16 w
16 w
18 w
20 w
20 w
15 and 22 w
24 w
18 and 30 w
2, 7, and 15 m
3m

344.7 versus 314.1∗ [15] and 333.1 versus 296.7∗ [22] (bpm)
322 versus 328 bpm NSD
NSD
453 versus 454 bpm NSD
369 versus 417 bpm NSD
208 versus 217 bpm NSD
341 versus 360 bpm NSD
344.7 versus 314.1∗ [15] and 333.1 versus 296.7∗ [22] (bpm)
370.33 versus 323.00∗ (bpm)
337 versus 350 [18] and 319 versus 328 bpm [30] NSD
370 versus 316∗ [2], 324 versus 264∗ [7], and 307 versus 256∗ [15] (bpm)
NSD

[34]
[28]
[37]
[30]
[31]
[32]
[33]
[34]
[2]
[45]
[46]
[58]

15 and 22 w
14–16 w

122.3 versus 138.4∗ [15] and 117.5 versus 135.0∗ [22] (mmHg)
131 versus 134 mmHg NSD
Higher∗

[34]
[28]
[30]
[31]

20 w

145 versus 123 mmHg NSD
117 versus 121 mmHg NSD
Higher∗

20 w
15 and 22 w
3m

144 versus 149 mmHg NSD
122.3 versus 138.4∗ [15] and 117.5 versus 135.0∗ [22] (mmHg)
124 versus 152∗ (mmHg)

[33]
[34]
[58]

DBP

15 and 22 w
16 w
15 and 22 w

88.1 versus 95.4∗ [15] and 84.0 versus 91.6 [22] (mmHg)
117 versus 89∗ (mmHg)
88.1 versus 95.4∗ [15] and 84.0 versus 91.6 mmHg [22]

[34]
[30]
[34]

16 w
16 w

117 versus 120 mmHg NSD
Higher∗

[35]

MAP

16 w

126 versus 100∗ (mmHg)

[30]

HR

16 w
SBP

16 w
18 w

[37]

[32]

[37]

PLVP

18 and 30 w

106 versus 105 [18] and 112 versus 108 mmHg [30] NSD

[45]

LV +dP/dt

18 and 30 w
26 w

6510 versus 5953 [18] and 6846 versus 5840 mmHg/s [30] NSD
NSD

[45]
[30]

LV –dP/dt

18 and 30 w
26 w

4800 versus 4614 (18) and 5166 versus 5111 mmHg/s [30] NSD
NSD

[45]
[30]

LVEDP

18 and 30 w

8 versus 6 [18] and 9 versus 6∗ [30] (mmHg)

[45]

LVEDV

20 w

550 versus 713 μl NSD

[32]

LVDV

6m

411.69 versus 415.53 μl NSD

[51]

LVSV

6m

108.51 versus 196.01∗ (μl)

[51]

∗

EF

14–16 w
16 w
20 w
26 w
6m

80 versus 73 (%)
NSD
77.9 versus 80.5% NSD
0.74 versus 0.93∗ (%)
73.42 versus 52.63∗ (%)

[28]
[30]
[33]
[44]
[51]

FS

20 w
20 w
24 w
6m
18 and 30 w

47 versus 30∗ (%)
42.3 versus 45.3% NSD
43.45 versus 38.20% NSD
44.41 versus 28.56∗ (%)
51 versus 55 [18] and 49 versus 51 cm [30] NSD

[32]
[33]
[2]
[51]
[45]
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Table 6: Continued.

Parameter

Age

Control versus GK

Reference

CO

20 w
6m

368 versus 321 ml/min NSD
303.7 versus 219.52∗ (μl)

[33]
[51]

IVCT

24 w

10.98 versus 12.26∗ (ms)

[2]

IVRT

14–16 w
24 w

25.3 versus 28.3∗ (ms)
19.09 versus 24.88 ms

[28]
[2]

15 w

Increased∗

[29]

CBF

∗

24 w

4.32 versus 2.46 (mL/g/min)

[2]

HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; PLVP: peak left ventricular pressure; LV +dP/dt: rate
for pressure development in left ventricle; LV –dP/dt: rate for pressure decline in left ventricle; LVEDP: left ventricular end diastolic pressure; LVEDV: left
ventricular end diastolic volume; LVDV: left ventricular diastolic volume; LVSV: left ventricular systolic volume; EF: ejection fraction; FS: fractional
shortening; CO: cardiac output; IVCT: isovolumic contraction time; IVRT: isovolumic relaxation time; CBF: coronary blood ﬂow; NSD: no signiﬁcant
diﬀerence. ∗ Signiﬁcant diﬀerence.

Table 7: Isolated heart hemodynamic function in the GK rat.
Parameter

Age

Control versus GK

Reference

18 w
5–8 m
9–14 m
18 m

237 versus 213 bpm NSF
251.8 versus 259.5 bpm NSD
267 versus 271 bpm NSD
138 versus 115 bpm NSD

[31]
[10]
[11]
[50]

18 w

44 versus 52 mmHg NSD
Reduced∗

[31]

126.6 versus 119.8 mmHg NSD
Reduced∗

[10]

6m
16 w
9–14 m

NSD
76 versus 63 mmHg NSD

[35]
[11]

RPP

16 w

NSD

[35]

EDP

9–14 m

8 versus 10 mmHg NSD

[11]

LV +dP/dt

18 w
5–8 m

1365 versus 1602 mmHg/s NSD
3390.6 versus 3169.5 mmHg/s NSD
Reduced∗

[31]
[10]

−945 versus −1032 mmHg/s NSD
−2669.0 versus −2672.0 mmHg/s NSD
Reduced∗

[31]
[10]

HR

LVP

6m
5–8 m

LVDP

6m
LV −dP/dt

18 w
5–8 m
6m

CF
CPP

∗

[51]
[51]

[51]

[51]
[31]
[10]

9–14 m

7.1 versus 5.8 (ml/min)
10.9 versus 9.8 ml/min/g NSD
Reduced∗

5–8 m

74.2 versus 76.6 mmHg NSD

[10]

18 w
5–8 m

[11]

HR: heart rate; LVP: left ventricular pressure; LVDP: left ventricular developed pressure; RPP: rate pressure product; EDP: end diastolic pressure;
LV +dP/dt: rate for pressure development in left ventricle; LV –dP/dt: rate for pressure decline in left ventricle; CF: coronary ﬂow; CPP: coronary perfusion
pressure; NSD: no signiﬁcant diﬀerence. ∗ Signiﬁcant diﬀerence.

It should be noted that the main function of the mitochondria in the heart is to produce energy in the form of
ATP, which is required for cardiac contractile activity. However, mitochondria are known to serve as Ca2+ sinks in the
cell by acting as a local buﬀering system, removing Ca2+
and modulating cytosolic Ca2+concentrations [65, 109]. In
addition to controlling their intraorganelle Ca2+ concentration, mitochondria dynamically interact with the cytosol

and intracellular Ca2+ handling machineries to shape the
cellular Ca2+ signaling network [65]. Recent evidence suggests that there is a dynamic exchange of Ca2+ between
the mitochondria and the cytosol and that mitochondrial
Ca2+ uptake increases mitochondrial ATP production
[110]. Therefore, mitochondria can play an important
role in preventing and/or delaying the occurrence of
intracellular Ca2+ overload in cardiomyocytes under
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Table 8: Myocyte contraction from the GK rat heart.

Parameter

Age

Control versus GK

Reference

MD

8w
18 m

9.11 versus 9.93∗ (μm)
9.43 versus 11.34∗ (μm)

[36]
[40]

16 w

Increased∗

[30]

6m

Increased∗

[51]

20 w

Increased∗

[33]

8–10 w
5–8 m
10 m

[41]
[10]
[47]

10-11 m

NSD
NSD
139.48 versus 155.63∗ (μm)
Increased∗

[48]

17 m
18 m

109.7 versus 109.3 μm NSD
139.8 versus 146.4 μm NSD

[39]
[50]

14–16 w

Increased∗

[28]

SA
CSA

RCL

CP

∗

TPK

8–10 w
10 m
10-11 m
17 m
18 m

115.03 versus 125.38 (ms)
119.77 versus 136.15∗ (ms)
NSD
302.7 versus 337.5∗ (ms)
119.9 versus 115.1 ms NSD

[41]
[47]
[48]
[39]
[50]

THALF

8–10 w
10 m
10-11 m
18 m
17 m

NSD
NSD
NSD
75.2 versus 65.1∗ (ms)
231.3 versus 275.4∗ (ms)

[41]
[47]
[48]
[50]
[39]

AMP

8–10 w
5–8 m
10 m
10-11 m
17 m
18 m

NSD
NSD
6.52 versus 7.15% NSD
NSD
5.05 versus 6.56∗ (%)
6.7 versus 6.5% NSD

[41]
[10]
[47]
[48]
[39]
[50]

MD: myocyte diameter; SA: surface area; CSA: cross-sectional area;
RCL: resting cell length; CP: cell capacitance; TPK: time to peak
shortening; THALF: time to half relaxation of shortening; AMP: amplitude
of shortening; NSD: no signiﬁcant diﬀerence. ∗ Signiﬁcant diﬀerence.

diﬀerent pathological conditions. For example, during the
development of cardiac dysfunction and intracellular Ca2+
overload in chronic diabetes, mitochondria are believed to
continue accumulating Ca2+, thereby serving as a protective
mechanism [65, 71]. However, when the intramitochondrial
Ca2+ concentration exceeds its buﬀering capacity, irreversible swelling occurs leading to mitochondrial dysfunction.
As a result, energy production as well as energy stores
are depleted. Collectively, these defects may contribute
to the development of cardiac dysfunction in diabetic
cardiomyopathy [109].
Evidence of deﬁcits in mitochondrial Ca2+ handling
has been demonstrated in animal models of both type 1
and type 2 diabetes. For example, in streptozotocin(STZ-) induced diabetic rats, hyperglycemia was associated
with lower rates of mitochondrial Ca2+ uptake [107]. This
reduction can be explained by the increased opening of

Table 9: Myocyte calcium from the GK rat heart.
Parameter

Age

Control versus GK

Reference

RCa2+

14–16 w
8–10 w
5–8 m
10 m
10-11 m
17 m
18 m

0.97 versus 1.25∗ (RU)
NSD
NSD
NSD
NSD
1.32 versus 1.23 RU NSD
1.28 versus 1.31 RU NSD

[28]
[41]
[10]
[47]
[48]
[39]
[50]

TPK

8–10 w
NSD
10 m
55.82 versus 66.14∗ (ms)
10-11 m
NSD
17 m
91.7 versus 104.3 ms NSD
18 m
64.8 versus 66.6 ms NSD

[41]
[47]
[48]
[39]
[50]

THALF

8–10 w 183.46 versus 148.32∗ (ms)
10 m
NSD
10-11 m
NSD
17 m 199.1 versus 199.0 ms NSD
18 m 136.2 versus 123.1 ms NSD

[41]
[47]
[48]
[39]
[50]

AMP

8–10 w
5–8 m
10 m
10-11 m
17 m
18 m

NSD
NSD
0.25 versus 0.31 (RU)
NSD
0.30 versus 0.23∗ (RU)
0.50 versus 0.78∗ (RU)

[41]
[10]
[47]
[48]
[39]
[50]

ICaL amplitude 10-11 m

NSD

[48]

ICaL
inactivation

10-11 m

NSD

[48]

ICaL restitution 10-11 m

NSD

[48]

MS Ca

2+

17 m

∗

31.9 versus 89.2 (μm/RU)

[39]

RCa2+: resting Ca2+; TPK: time to peak Ca2+ transient; THALF: time to
half decay of the Ca2+ transient; AMP: amplitude of the Ca2+ transient;
ICaL: L-type Ca2+ current; MSCa2+: myoﬁlament sensitivity to Ca2+;
NSD: no signiﬁcant diﬀerence. ∗ Signiﬁcant diﬀerence.

the mitochondrial permeability transition pore (MPTP),
resulting in the release of accumulated Ca2+. In STZinduced diabetic rats, Oliveira et al. observed that Ca2+
uptake was similar in control versus diabetic hearts;
however, mitochondria in diabetic hearts were unable to
retain the accumulated Ca2+. This eﬀect was not observed
in the presence of cyclosporin, an MPTP inhibitor [108]. In
type 2 diabetic ob/ob mice, reduced intracellular Ca2+
release upon electrical stimulation, slowed intracellular
Ca2+ decay rate, and impaired mitochondrial Ca2+ handling
were observed [111, 112]. Similarly, Belke et al. observed a
reduction in Ca2+ levels and a reduction in the rate of
Ca2+ decay in isolated cardiomyocytes from db/db animals,
suggesting impaired mitochondrial Ca2+ uptake [113].
Taken together, these studies support the notion that
mitochondrial Ca2+ handling is impaired in diabetic myocardium, resulting in compromised energy metabolism and
thus reduced contractility.
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9. Conclusion
Although diabetic cardiomyopathy is a frequent and important complication of DM, its physiological bases are still not
completely understood. The GK type 2 diabetic heart displays a variety of abnormal hemodynamic characteristics
in vivo and in the isolated perfused heart. Hyperglycemia is
usually associated with alterations in heart rate, blood pressure, blood pumping capability, and/or coronary blood ﬂow.
Contractile function, in terms of amplitude and kinetics of
shortening, is frequently disturbed in the GK type 2 diabetic
heart. Several mechanisms may contribute to cardiac dysfunction including mitochondrial dysfunction, myocardial
ﬁbrosis, hypertrophy, and apoptosis. Many studies show no
change in L-type Ca2+ current despite the reduction in both
contractions and Ca2+ transient. Instead, reduction of Ca2+
transients and the consequent contractile dysfunction may
be attributed to both depletion of SR Ca2+, which may result
from RyR-dependent Ca2+ leak, an increased Ca2+ extrusion
through NCX, or a reduced function of SERCA (Figure 1).
Understanding the molecular mechanism(s) of altered Ca2+
signaling will provide opportunities for the development of
new treatments to improve heart function in T2DM patients.

DM:
CVDs:
T2DM:
GK:

Diabetes mellitus
Cardiovascular diseases
Type 2 diabetes mellitus
Goto-Kakizaki

Glucose transporter
Glycerol-3-phosphate dehydrogenase
New Zealand obese
Otsuka Long Evans Tokushima Fat
Spontaneously diabetic Torri
Transforming growth factor-β1
Extracellular matrix
Protein kinase B
Excitation-contraction coupling
Sarcoplasmic reticulum
Ryanodine receptor
Calcium-induced calcium release
SR Ca2+-ATPase2
Na+/Ca2+ exchanger
Endocardial
Epicardial.

Myofilaments

Figure 1: Schematic diagram showing the summary of some of the
proposed mechanisms involved in the alterations in Ca2+ signaling
in cardiac myocyte from the GK diabetic heart. (1) No change/or
decrease in L-type Ca2+ channel activity, (2) increase in Na+/Ca2+
exchange current, (3) decrease in SR Ca2+ content, (4) decrease
in SR Ca2+ uptake, and (5) increase in Ca2+ release through RYR.
SR: sarcoplasmic reticulum; RYR: ryanodine receptor; SERCA:
sarcoplasmic reticulum Ca2+-ATPase; NCX: Na+/Ca2+ exchanger;
—: no eﬀect; ↑: increased activity; ↓: decreased activity (adapted
from Eisner, 2013).
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